OncoMatch/Clinical Trials/NCT06783829
A Study of SHR-4394 Injection in Subjects With Prostate Cancer
Is NCT06783829 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies SHR4394 for prostate cancer.
Treatment: SHR4394 — This is an open label, multi-center, multiple dose Phase I study to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-4394 injection in subjects with prostate cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: luteinizing hormone releasing hormone analogue or bilateral orchidectomy
Continuous treatment with luteinizing hormone releasing hormone analogues (LHRHa) or previous bilateral orchidectomy
Cannot have received: systemic anticancer treatments or clinical investigational drugs
Exception: within 4 weeks prior to the initiation of the study treatment
Received systemic anticancer treatments or clinical investigational drugs 4 weeks prior to the initiation of the study treatment
Lab requirements
Blood counts
Kidney function
Liver function
Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify